ReviewCurrent cardiology reports2017
The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk.
Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Bone microarchitectural degradation in hypertensive patients: a population-based study.Archives of osteoporosis · 2026Article
- Thiazide diuretic use is associated with fewer hardware complications after anterior cervical discectomy and fusion.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
- Impact of Medications for Stable Angina Pectoris on Osteoporosis: A Review of Current Evidence.Journal of multidisciplinary healthcare · 2025Review
- The evaluation of the effect of long-term antihypertensive drug usage on bone density with dental volumetric tomography.Journal of clinical and experimental dentistry · 2024Article
- Cross-Disciplinary Approach of Adrenal Tumors: Insights into Primary Aldosteronism-Related Mineral Metabolism Status and Osteoporotic Fracture Risk.International journal of molecular sciences · 2023Review
- Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesisFrontiers in endocrinology · 2023Article
- Estimating the Incidence and Key Risk Factors of Cardiovascular Disease in Patients at High Risk of Imminent Fracture Using Routinely Collected Real-World Data From the UK.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Antihypertensive Drugs and Risk of Bone Fractures.Drugs & aging · 2022Review
- Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus.Nature reviews. Endocrinology · 2021Review
- Regulation of bone metabolism mediated by β-adrenergic receptor and its clinical application.World journal of clinical cases · 2021Review
- Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.Journal of materials research · 2021Article
- Diabetes and Bone Fragility.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Review
- Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review).Journal of clinical medicine · 2020Review
- Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism.Endocrine · 2020Article
- Evaluation of the effects of β1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal womenTurkish journal of medical sciences · 2020Article
- Metabolic factors and hip fracture risk in a large Austrian cohort study.Bone reports · 2020Article
- Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.Journal of endocrinological investigation · 2020Observational
- Association between the Use of Angiotensin-Blocking Medications with Hip Fracture and Death in Older People.The Journal of frailty & aging · 2020Article
- Forearm bone density is not elevated in Inuit women with impaired fasting glucose or type 2 diabetes mellitus.International journal of circumpolar health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes the impact of thiazide diuretics on fracture risk in older hypertensive individuals. RECENT
findingsWe performed a post hoc evaluation of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, a randomized, prospective, double blind hypertension study comparing a thiazide-like diuretic, a calcium channel blocker (CCB), and an angiotensin converting enzyme inhibitor (ACEi). We examined the risk of hip and pelvic fractures during the in-trial period (n = 22,180 participants; mean 4.9-year follow-up) and during the post-trial period using national data bases (n = 16,622 participants) (mean total follow-up 7.8 years). During the trial, participants randomized to the thiazide diuretic versus the CCB or the ACEi had a lower risk of fracture on adjusted analyses (HR 0.79 [95% CI, 0.63, 0.98], p = 0.04). Risk of fracture was significantly lower in participants randomized to the diuretic as compared to those randomized to the ACEi (HR 0.75 [95% CI, 0.58, 0.98]; p = 0.04), but not significantly different compared to the CCB (HR 0.87 [95% CI, 0.71, 1.09]; p = 0.17). Over the entire trial and post-trial period of follow-up, the cumulative incidence of fractures was non-significantly lower in participants assigned to the diuretic vs assignment to the ACEi or the CCB (HR 0.87 [0.74-1.03], p = 0.10) and versus each medication separately. These findings establish a benefit for thiazide diuretic treatment for the prevention of fractures versus other commonly used antihypertensive medications using prospective, randomized data. The effects of the thiazide diuretic on bone appear to be long lasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.